Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01298921
Other study ID # 2010-0205
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date January 2011
Est. completion date July 2012

Study information

Verified date April 2019
Source Geisinger Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cluster headache is a disorder marked by frequent attacks of short-lasting, severe, unilateral head pain with associated autonomic symptoms. It is the most severe head pain syndrome known. Currently, the two most common treatments for cluster headaches are inhaled oxygen and injectable sumatriptan. These treatments do not work for all cluster headache patients, and patients who smoke may eventually develop contraindication to triptans. New treatment options are needed.

An alternative method of oxygen delivery (as opposed to continuous flow) uses a demand valve that is controlled by respiration rate, allowing increased oxygen flow in response to increased demand. This system may be more efficacious at stopping a cluster headache attack than the currently prescribed oxygen delivery system.

This study will compare the effectiveness of oxygen delivered via demand valve versus continuous high flow oxygen via non-rebreather face mask in the acute treatment of a cluster headache attack. All patients will treat one cluster headache with each of the 2 treatment methods.


Description:

Cluster headache is a primary headache disorder marked by frequent attacks of short-lasting, severe, unilateral head pain with associated autonomic symptoms. The goal of acute therapy for cluster headache is fast, effective and consistent relief.

In the currently recommended dosing strategy of continuous flow 100% oxygen given via a non-rebreather face mask at 7-15L/min, the time to improvement can sometimes take upwards of 20-30 minutes and is not effective for all cluster headache sufferers.

An alternative method of oxygen delivery (versus continuous flow) uses a demand valve which is controlled by the respiration rate, allowing increased oxygen flow in response to increased demand. This delivery system may be better at stopping a cluster headache attack than the continuous flow model as it can support hyperventilation which can enhance cerebral arterial vasoconstriction via a state of hyperoxia and hypocapnia. Arterial vasoconstriction is one hypothesized method by which oxygen can abort a cluster headache attack.

This proof of concept trial will evaluate if oxygen delivered via demand valve with a specific breathing technique is effective as a cluster headache acute treatment and is more effective than the traditional continuous high flow oxygen treatment with a non-rebreather face mask.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date July 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Men or women 18 to 65 with history of moderate severe or very severe cluster headaches and currently in a cluster headache period or cycle are included.

Exclusion Criteria:

- Subjects who have a history of chronic obstructive lung disease, those who have major neurologic disorders other than cluster headaches, those with a history of syncope, or lightheadedness with hyperventilation and pregnant women are excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oxygen
A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
Oxygen
100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes

Locations

Country Name City State
United States Geisinger Wyoming Valley Wilkes-Barre Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Geisinger Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction in Headache Pain Headache response after 30 minutes of oxygen treatment. Headache response is defined as a reduction in headache pain intensity from moderate, severe, or very severe pain to mild or no pain. 30 minutes
Secondary Headache Relief and Pain Free Percentage of patients with no pain after 30 minutes of treatment
Headache relief and pain free at other time points (5 to 60 minutes)
Reduction of autonomic symptoms at 30 minutes
Any difference in treatment response between episodic and chronic cluster headache patients (if patient #'s allow)
Rescue medication use
Cluster headache recurrence by 24 hours post oxygen treatments
Patient satisfaction with treatment response compared with prior oxygen treatment if have utilized8.Likelihood of choosing this technique again to treat a cluster headache attack
5 to 60 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT05264714 - Cluster Headache Treatment With Rimegepant Phase 2
Completed NCT01677026 - Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
Terminated NCT00203190 - A Double-Blind, Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache Phase 4
Recruiting NCT04570475 - High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache Phase 3
Completed NCT04066023 - Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches Phase 2/Phase 3
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT02019017 - Botox Injection in Treatment of Cluster Headache Phase 1/Phase 2
Recruiting NCT05153876 - An Open Internet-based Survey and Natural Language Processing Project Analysing Written Monologues by Headache Patients
Recruiting NCT05324748 - Repeated GON Injections in CCH Phase 3
Completed NCT02782533 - DBS of the Third Ventricle for Cluster Headache and Obesity N/A
Completed NCT04179266 - Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache Phase 1/Phase 2
Recruiting NCT04406259 - Atrioventricular Block and Cluster Headache (SEVA) Phase 4
Recruiting NCT06206772 - Resting State Functional Connectivity in Cluster Headache
Recruiting NCT03944876 - Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache Phase 3
Not yet recruiting NCT05857098 - Detection of Local Field Potentials in the Ventral Tegmental Area of the Midbrain in Chronic Cluster Headache Patients
Recruiting NCT02910323 - The Will Erwin Headache Research Center - Cluster Headache Study
Terminated NCT00458770 - Study of Hypothalamic Metabolism in Spontaneous Cluster Headache Attacks N/A
Completed NCT00662935 - Evaluation of Efficacity and Safety of Deep Brain Stimulation (DBS) in Chronic and Treatment-Resistant Cluster Headache(CH) N/A
Active, not recruiting NCT03511846 - Pain Biomarker Study Phase 1
Completed NCT00184587 - Prophylactic Treatment of Episodic Cluster Headache Phase 2

External Links